miR-155 and miR-484 Are Associated with Time to Progression in Metastatic Renal Cell Carcinoma Treated with Sunitinib

Figure 2

Kaplan-Meier survival curves estimating TTP in sunitinib treated mRCC patients () according to miR-155 ((a); value < 0.01) and miR-484 ((b); value < 0.05) tumor tissue expression levels. Patients with low expression of the relevant miRNA are illustrated by dashed line.

(a)

(b)